Stockholders' Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Schedule of warrants

	2024				2023
	Number		Weighted Average Exercise Price		Number		Weighted Average Exercise Price
Beginning balance	7,444,698		$	1.68	5,678,836		$	1.84
Granted	11,631,035		0.34		1,765,862		1.17
Exercised	(10,331,035)		0.41		—		—
Ending balance	8,744,698		$	1.40	7,444,698		$	1.68
Intrinsic value of warrants	$	6,661,661			$	327,214
Weighted Average Remaining Contractual Life (Years)	3.86

Schedule of options

The following represents a summary of options for the Amended Plan and additional options granted outside of the Amended Plan for the years ended December 31, 2024 and 2023:

	Number of Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in Years)	Weighted-Average Fair Value
Outstanding, December 31, 2022	6,425,000	$	2.69	6.21	$	4.26
Granted	1,932,500	1.48		6.19	1.10
Exercised	—	—
Forfeited	(114,063)	2.00
Outstanding December 31, 2023	8,243,437	2.38		4.76	3.55
Granted	1,900,000	0.22		6.49	0.19
Exercised	—	—
Forfeited	(628,437)	1.55
Outstanding December 31, 2024	9,515,000	$	2.03	3.89	$	3.12
As of December 31, 2024
Vested and Exercisable	6,367,785	$	2.22	3.81	$	2.77

Schedule of Stock Options, Valuation Assumptions

The Company measures the share-based compensation on the grant date using the following assumptions:

	Year Ended December 31,
	2024	2023	2022
Expected term	7 years	7 years	7 years
Expected volatility	123.05% - 124.33%	161.61% - 166.14%	135.00% – 177.00%
Expected dividend yield	—	—	—
Risk-free interest rate	3.89% - 4.45%	3.48% - 3.89%	0.10	%